Hypera S.A.

São Paulo Stock Exchange HYPE3.SA

Hypera S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD -388.03 M

Hypera S.A. Net Cash Used Provided By Financing Activities is USD -388.03 M for the year ending December 31, 2023, a -838.33% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Hypera S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 52.56 M, a -47.32% change year over year.
  • Hypera S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 99.77 M, a -83.82% change year over year.
  • Hypera S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 616.43 M, a 2,917.31% change year over year.
  • Hypera S.A. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 20.43 M, a 110.30% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
São Paulo Stock Exchange: HYPE3.SA

Hypera S.A.

CEO Mr. Breno Toledo Pires de Oliveira
IPO Date April 18, 2008
Location Brazil
Headquarters Av. Magalhães de Castro, 4800
Employees 10,301
Sector Health Care
Industries
Description

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

Similar companies

RENT3.SA

Localiza Rent a Car S.A.

USD 4.81

2.16%

RADL3.SA

Raia Drogasil S.A.

USD 3.45

0.69%

QUAL3.SA

Qualicorp Consultoria e Corretora de Seguros S.A.

USD 0.25

1.92%

FLRY3.SA

Fleury S.A.

USD 1.91

1.25%

StockViz Staff

January 15, 2025

Any question? Send us an email